BioIVT, a portfolio company of private equity firm Linden Capital Partners and formerly known as BioreclamationIVT, announced on September 26 its acquisition of Fidelis Research, a Sofia, Bulgaria-headquartered provider of biospecimen collection, laboratory processing and analysis, clinical research and patient support programs. Terms of the deal were not disclosed.
With this acquisition, Westbury, New York-based BioIVT will be able to expand its support of precision medicine research in multiple therapeutic areas, most notably in oncology.
Fidelis Research is an 85-site clinical biospecimen collection network in southeastern Europe. The company also has cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organizations.
BioIVT is a global provider of biological specimens. It specializes in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids.
According to the LevinPro HC database, this marks the 412th Other Services transaction of 2022 and the 29th acquisition of a contract research organization. This is also BioIVT’s fourth acquisition since it was acquired by Linden Capital Partners in October 2021. The company acquired Tennessee Blood Services in April 2022, Cypex in August 2022 and Xenotech in September 2022.
